Oral Presentation ESA-SRB-NZSE-CaSR 2026 in conjunction with ENSA

Investigating the role of anti-angiogenic FKBPL in trophoblast differentiation (144012)

Ananya Raman 1 , Taj Graham 1 , Maia McCalmont Parkinson 1 , Claire Richards 1 2 , Louise Cole 3 , Lana McClements 1 2
  1. School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
  2. Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
  3. Australian Institute for Microbiology and Infection (AIMI), Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
Publish consent withheld
  1. Todd N, McNally R, et al. Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment. Journal of Clinical Endocrinology and Metabolism 2021;106(1): 26–41.
  2. McClements L, Yakkundi A, et al. Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway. Clinical Cancer Research 2013;19(14):3881-3893.